Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Company profile
Website
CEO
Joseph E. Payne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alcobra LTD.
SEC CIK
Corporate docs
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
10 Jan 24
UPLOAD
Letter from SEC
4 Sep 19
CORRESP
Correspondence with SEC
16 Aug 19
UPLOAD
Letter from SEC
6 Aug 19
8-K
Entry into a Material Definitive Agreement
1 Aug 19
S-8
Registration of securities for employees
21 Jun 19
8-K
License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
20 Jun 19
8-K
Submission of Matters to a Vote of Security Holders
20 May 19
8-K
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update
13 May 19
10-Q
2019 Q1
Quarterly report
13 May 19
Latest ownership filings
SC 13G/A
Arcturus Therapeutics Ltd.
14 Feb 20
SC 13G/A
Arcturus Therapeutics Ltd.
20 Feb 19
SC 13G
Arcturus Therapeutics Ltd.
14 Feb 19
4
Pad Chivukula
11 Feb 19
4
Keith C Kummerfeld
11 Feb 19
4
Joseph E Payne
11 Feb 19
SC 13G/A
Arcturus Therapeutics Ltd.
25 Jan 19
3
Keith C Kummerfeld
2 Jan 19
3
Pad Chivukula
2 Jan 19
3
Joseph E Payne
2 Jan 19
Institutional ownership, Q3 2023
99.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 24 |
Closed positions | 22 |
Increased positions | 50 |
Reduced positions | 50 |
13F shares | Current |
---|---|
Total value | 634.62 bn |
Total shares | 26.31 mm |
Total puts | 205.90 k |
Total calls | 203.70 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 4.71 mm | $120.38 bn |
BLK Blackrock | 2.14 mm | $54.62 bn |
ARK Investment Management | 1.90 mm | $48.58 bn |
STT State Street | 1.67 mm | $42.62 bn |
Vanguard | 1.41 mm | $35.94 bn |
CMTDF Sumitomo Mitsui Trust | 1.39 mm | $35.48 bn |
Nikko Asset Management Americas | 1.39 mm | $35.42 bn |
RARE Ultragenyx Pharmaceutical | 1.20 mm | $53.48 mm |
Woodline Partners | 1.07 mm | $27.33 bn |
Dimensional Fund Advisors | 973.84 k | $24.88 bn |